Patents by Inventor Stuart Rosenblum
Stuart Rosenblum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8609635Abstract: The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M1, X1 and X2 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.Type: GrantFiled: March 4, 2011Date of Patent: December 17, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Anilkumar Gopinadhan Nair, Kartik M. Keertikar, Seong Heon Kim, Joseph A. Kozlowski, Stuart Rosenblum, Oleg B. Selyutin, Michael Wong, Wensheng Yu, Qingbei Zeng
-
Publication number: 20110223134Abstract: The present invention relates to novel Fused Tricyclic Silyl Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, D, M1, X1 and X2 are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Silyl Compound, and methods of using the Fused Tricyclic Silyl Compounds for treating or preventing HCV infection in a patient.Type: ApplicationFiled: March 4, 2011Publication date: September 15, 2011Inventors: Anilkumar Gopinadhan Nair, Kerry M. Keertikar, Seong Heon Kim, Joseph A. Kozlowski, Stuart Rosenblum, Oleg B. Selyutin, Michael Wong, Wensheng Yu, Qingbei Zeng
-
Publication number: 20080058343Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.Type: ApplicationFiled: July 12, 2007Publication date: March 6, 2008Inventors: Stuart Rosenblum, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Douglas Hobbs
-
Publication number: 20080039474Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1. or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.Type: ApplicationFiled: March 19, 2007Publication date: February 14, 2008Inventors: STUART ROSENBLUM, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Douglas Hobbs
-
Publication number: 20070082913Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: ApplicationFiled: October 10, 2006Publication date: April 12, 2007Inventors: Seong Kim, Bandarpalle Shankar, Joseph Kozlowski, Stuart Rosenblum, Neng-Yang Shih
-
Publication number: 20070054919Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: ApplicationFiled: February 14, 2006Publication date: March 8, 2007Inventors: Stuart Rosenblum, Seong Kim, Qingbei Zeng, Michael Wong, Gopinadhan Anilkumar, Yueheng Jiang, Wensheng Yu, Joseph Kozlowski, Neng-Yang Shih, Bandarpalle Shankar, Brian McGuinness, Guizhen Dong, Lisa Zawacki, Douglas Hobbs, John Baldwin, Yuefei Shao
-
Publication number: 20070021611Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: ApplicationFiled: February 14, 2006Publication date: January 25, 2007Inventors: Brian McGuinness, Stuart Rosenblum, Joseph Kozlowski, Gopinadhan Anilkumar, Seong Kim, Neng-Yang Shih, Chung-Her Jenh, Paul Zavodny, Douglas Hobbs, Guizhen Dong, Yuefei Shao, Lisa Zawacki, Cangming Yang, Carolyn Carroll
-
Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
Publication number: 20070015807Abstract: Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M1 and M3 are CH or N; M2 is CH, CF or N; Y is —C(?O)—, —C(?S)—, —(CH2)q—, —C(?NOR7)— or —SO1-2—; Z is a bond or optionally substituted alkylene or alkenylene; R1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R3 is H, —C(O)NH2, or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other ageType: ApplicationFiled: June 19, 2006Publication date: January 18, 2007Inventors: Robert Aslanian, Michael Berlin, Christopher Boyce, Jianhua Chao, Manuel de Lera Ruiz, Pietro Mangiaracina, Kevin McCormick, Mwangi Mutahi, Stuart Rosenblum, Neng-Yang Shih, Daniel Solomon, Wing Tom, Henry Vaccaro, Junying Zheng, Xiaohong Zhu -
Publication number: 20060276480Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: ApplicationFiled: February 14, 2006Publication date: December 7, 2006Inventors: Michael Wong, Youheng Shu, Wensheng Yu, Stuart Rosenblum, Joseph Kozlowski, Brian McGuinness, Yuefei Shao, Douglas Hobbs
-
Publication number: 20060276479Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: ApplicationFiled: February 14, 2006Publication date: December 7, 2006Inventors: Seong Kim, Gopinadhan Anilkumar, Michael Wong, Qingbei Zeng, Stuart Rosenblum, Joseph Kozlowski, Yuefei Shao, Brian McGuinness, Douglas Hobbs
-
Publication number: 20060276448Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts or solvates of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: and the pharmaceutically acceptable salts, solvates or esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.Type: ApplicationFiled: February 14, 2006Publication date: December 7, 2006Inventors: Qingbei Zeng, De-Yi Yang, Stuart Rosenblum, Michael Wong, Gopinadhan Anilkumar, Seong Kim, Wensheng Yu, Joseph Kozlowski, Neng-Yang Shih, Brian McGuinness, Lisa Guise-Zawacki, Doublas Hobbs
-
Publication number: 20060276457Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.Type: ApplicationFiled: February 14, 2006Publication date: December 7, 2006Inventors: Wensheng Yu, Seong Kim, Gopinadhan Anilkumar, Stuart Rosenblum, Bandarpalle Shankar, Brian McGuinness, Douglas Hobbs, Yuefei Shao
-
Publication number: 20060217392Abstract: The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prod rug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, zenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.Type: ApplicationFiled: February 14, 2006Publication date: September 28, 2006Inventors: Gopinadhan Anilkumar, Qingbei Zeng, Stuart Rosenblum, Joseph Kozlowski, Brian McGuinness, Douglas Hobbs
-
Publication number: 20050113383Abstract: Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compounds of Formula I in combination with a H1 receptor antagonist.Type: ApplicationFiled: October 27, 2004Publication date: May 26, 2005Inventors: Stuart Rosenblum, Qingbei Zeng, Mwangi Mutahi, Robert Aslanian, Pauline Ting, Neng-Yang Shih, Daniel Solomon, Jianhua Cao, Henry Vaccaro, Kevin McCormick, John Baldwin, Ge Li
-
Patent number: 6518287Abstract: The present invention discloses novel substituted imidazole compounds which have either or dual histamine-H1 and H3 receptor antagonist activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such imidazoles as well as methods of using them to treat allergy, inflammatory and CNS-related diseases and others.Type: GrantFiled: September 18, 2001Date of Patent: February 11, 2003Assignee: Schering CorporationInventors: Robert G. Aslanian, Stuart Rosenblum, Mwangi Wa Mutahi, Neng-Yang Shih, John J. Piwinski
-
Patent number: 5238950Abstract: A method of inhibiting the binding of PDGF using compounds of the formula I ##STR1## useful in the treatment of atherosclerosis, cancer, retinal detachment, pulmonary fibrosis, arthritis, psoriasis and glomerulonephritis, and restenosis following angioplasty or vascular surgery is disclosed.Also disclosed are pharmaceutical compositions and novel PDGF inhibitory compounds of the formula ##STR2## or a pharmaceutically acceptable addition salt thereof, useful in the treatment of atherosclerosis, cancer, retinal detachment, pulmonary fibrosis, arthritis, psoriasis and glomerulonephritis, and restenosis following angioplasty or vascular surgery.Type: GrantFiled: December 17, 1991Date of Patent: August 24, 1993Assignee: Schering CorporationInventors: John W. Clader, Harry R. Davis, Deborra Mullins, Stuart Rosenblum, Jay Weinstein
-
Patent number: 4656289Abstract: Novel synthetic routes to (3a.alpha.,6a.alpha.)-1,3-dibenzyl hexahydro-1H-thieno[3,4-d]imidazol-2(3H)-one 5,5-dioxide, a known intermediate in the synthesis of biotin are provided.A novel synthetic route from this intermediate to biotin is also disclosed.Type: GrantFiled: October 25, 1984Date of Patent: April 7, 1987Assignee: The Research Foundation of State Univ. of New YorkInventors: Hans A. Bates, Stuart Rosenblum